Industry News
Pharmaceutical Industry News
Insulet is taking diabetes…
Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger
A long-running confirmatory trial…
A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal. The development comes just as the company and the FDA work to formally limit the indication of
Patients hoping to get their hands…
Patients hoping to get their hands on a cheaper copycat of Johnson & Johnson’s fading anti-inflammatory blockbuster Simponi may have to wait for a few months more, thanks to an FDA inspection this summer that
Neurology-focused patient…
Neurology-focused patient groups’ perception of the pharma industry’s corporate reputation remains on a downward slope.
Kimberly-Clark has placed an…
Kimberly-Clark has placed an ambitious bet on a troubled counterpart, agreeing to buy out Johnson & Johnson’s consumer health spinout Kenvue for $48.7 billion.
After Roche’s Gazyva won an FDA…
After Roche's Gazyva won an FDA approval in lupus-related kidney disease, a phase 3 study now shows the med's worth in systemic lupus erythematosus, the most common type of lupus.
High-ranking FDA official George…
High-ranking FDA official George Tidmarsh, M.D., has tendered his resignation after an unconventional LinkedIn diatribe landed the senior drug regulator at the center of a lawsuit and an internal probe.
Eli Lilly is allotting $3 billion…
Eli Lilly is allotting $3 billion to establish an oral medicines manufacturing facility in Katwijk, the Netherlands, the company said on Monday.
F.D.A. Drug Unit Chief Resigns, and Is Sued by Drug Company
The official, Dr. George Tidmarsh, has become embroiled in an ethical dispute and is now the target of a lawsuit over his actions involving certain drugs tied to a business associate.
Why Medicare Recipients Should Check Their 2026 Drug Plans Now
Fall enrollment is on. Some plans are raising premiums for Part D, which covers prescriptions, by $50 or more per month, while others are lowering them.
Caplyta, the crown jewel of…
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to unlock the lucrative major depressive disorder market as an adjunctive treatment to antidepressants.
Boosted again by strong sales of…
Boosted again by strong sales of Skyrizi and Rinvoq, AbbVie has jacked up its revenue forecast for 2025 for the third straight quarter. The Illinois drugmaker has raised its guidance by $400 million, now expecting
The American Academy of Pediatrics…
The American Academy of Pediatrics on Friday said it does not recommend the routine use of leucovorin for children with autism, citing limited evidence.
Gilead’s long-acting…
Gilead’s long-acting pre-exposure prophylaxis med Yeztugo has garnered $54 million in sales since its June launch in the U.S., the company reported, bolstering its HIV franchise as cell therapy sales continue to decline.
The regulatory framework around…
The regulatory framework around biopharmaceutical manufacturing is exacting and continuously evolving. Companies must meet diverse global requirements while staying agile enough to deliver on accelerated clinical and commercial timelines
Takeda tightened its pipeline in…
Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 study. Roche licensed a respiratory bispecific candidate in a potential $1 billion-plus deal. And
As Biogen continues to carve out…
As Biogen continues to carve out new markets for its recent launches, the company's legacy multiple sclerosis franchise is holding steady in the face of generic pressure.
With vaccine sales on the decline…
With vaccine sales on the decline across the industry, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. But in the third quarter, the company recorded encouraging sales of the vaccine,
Bristol Myers Squibb’s highly…
Bristol Myers Squibb’s highly anticipated Cobenfy just finished its first trip around the sun as an approved drug, posting results in line with expectations that leave investors wondering when an inflection point might arrive.
Despite the largest U.S. pharmacy…
Despite the largest U.S. pharmacy benefit manager knocking Zepbound off its formulary this summer, sales of Lilly’s dual-action obesity med continue to impress, thanks in no small part to the company’s direct-to-consumer sales channel LillyDirect.